General
Preferred name
NEFAZODONE
Synonyms
NEFAZODONE HYDROCHLORIDE ()
BMY-13754-1 ()
Dutonin ()
MJ-13754-1 ()
Serzone ()
BMY-13754 ()
Nefazodone (hydrochloride) ()
Nefazodone (hydrochloride) ()
Nefazodona ()
NEFAZODONE HCL ()
NSC-760344 ()
BMY 13754 ()
MJ 13,754-1 ()
Nefazodone-d6 (hydrochloride) ()
P&D ID
PD001694
CAS
82752-99-6
83366-66-9
1330236-06-0
Tags
available
drug
Approved by
FDA
First approval
1994
Drug indication
Major depressive disorder
cocaine dependence
Depression
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
DESCRIPTION Nefazodone is an antidepressant.
Marketed formulations may contain nefazodone hydrochloride (PubChem CID 54911). (GtoPdb)
DESCRIPTION Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction[1][2][3].
PRICE 86
DESCRIPTION Nefazodone (Nefadar) is an oral antidepressant that is an antagonist of postsynaptic 5-HT 2A receptor and 5-HT 2C receptor, and also inhibits the reuptake of norepinephrine, dopamine, and serotonin (SNDRI).
DESCRIPTION Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
PRICE 64
DESCRIPTION Nefazodone is a selective serotonin 5-HT2 receptor antagonist. It is an antidepressant under the development of Bristol-Myers Squibb. Its sale was discontinued in some countries due to the rare incidence of hepatotoxicity. (BOC Sciences Bioactive Compounds)
DESCRIPTION CRF1 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION 5-HT2A antagonist and 5-HT uptake inhibitor. Antidepressant (Tocriscreen Total)
DESCRIPTION Nefazodone hydrochloride is an antidepressant drug. It acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. (Enamine Bioactive Compounds)
DESCRIPTION Nefazodone hydrochloride (Serzone) is a serotoninergic modulating antidepressant that is used in therapy of depression, aggressive behavior and panic disorder. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
33
Axon Medchem Screening Library
1102
BOC Sciences Bioactive Compounds
nefazodone-cas-83366-66-9-item-78122
Cayman Chemical Bioactives
10012642
34264
ChEMBL Approved Drugs
CHEMBL623
CHEMBL1200492
ChEMBL Drugs
CHEMBL623
CHEMBL1200492
Drug Repurposing Hub
DrugBank
DB01149
DrugBank Approved Drugs
DB01149
DrugCentral
1890
DrugCentral Approved Drugs
1890
DrugMAP
DM4ZS8M
DrugMAP Approved Drugs
DM4ZS8M
DrugMatrix
Enamine Bioactive Compounds
EBC-12785
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101562
EUbOPEN Chemogenomics Library
EUB0000491
Guide to Pharmacology
7247
Ki Database
Nefazodone
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL623
MedChem Express Bioactive Compound Library
HY-119209
HY-B1396
NCATS Inxight Approved Drugs
27X63J94GR
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
nefazodone-hydrochloride
TargetMol Bioactive Compound Library
T3275
The Spectrum Collection
Tocris Bioactive Compound Library
2777
Tocriscreen Total
Withdrawn 2.0
w145
External IDs
60
Properties
(calculated by RDKit )
Molecular Weight
469.22
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
0
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
3
cLogP
3.55
TPSA
55.53
Fraction CSP3
0.44
Chiral centers
0.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
Cytochrome P450
5-HT
Adrenergic Receptor
ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4
Antidepressant
Primary Target
5-HT2A Receptors
MOA
Antagonist
5-HT2A Antagonists
5-HT Reuptake Inhibitors
ADRA1B gene modulator
adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor
Member status
virtual
ATC
N06AX06
Toxicity type
hepatic
Pathway
GPCR/G protein
Neuroscience
Metabolic Enzyme/Protease
Neuronal Signaling
Therapeutic Class
Antidepressants
Solubility
Soluble in DMSO
Recommended Cell Concentration
1 uM
Source data